Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) on December 1, 2020. The filing reports the appointment of a new senior executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation details:
- Base Salary: $350,000 annually.
- Signing Bonus: $50,000.
- Relocation Expenses: $50,000 (subject to tax gross-up).
- Target Bonus: Up to 40% of base salary, contingent on performance targets.
- Equity Grant: Options to purchase 350,000 shares of common stock.
Material Changes
The primary material change reported is the appointment of Hui Liu, Ph.D., M.B.A., as Chief Technology Officer, effective December 1, 2020. Dr. Liu joins from Seqirus USA Inc., where he served as Director of Formulation and Delivery from 2017 to 2020.
Outlook, Risks, and Contingencies
Severance Provisions: The employment agreement includes specific contingencies for termination "without cause" or resignation for "good reason," providing for 12 months of base salary continuation and COBRA benefits. In the event of a "change of control" within 12 months of termination, 100% of outstanding equity awards vest immediately, and the target annual bonus is paid.
Legal Obligations: Dr. Liu has executed a standard Covenants Agreement regarding non-disclosure and assignment of inventions. Severance obligations cease immediately if Dr. Liu breaches this agreement or fails to execute a release agreement.
Investor Verification Checklist
- Verify the impact of the new CTO appointment on the company's clinical development pipeline.
- Review the full Employment Agreement (to be filed as an exhibit to the 2020 Form 10-K) for detailed performance metrics tied to the bonus structure.
- Assess the dilution impact of the 350,000 share option grant relative to the current outstanding share count.
- Confirm the company's cash position to ensure it can support the immediate cash outflows for the signing bonus and relocation expenses.